Wu Xinchun, Zhu Junxi, Yan Yichao, Niu Dongfeng, Chen Lin, Ning Ning, Zhang Yankai
Department of Gastrointestinal Surgery, Peking University International Hospital, Beijing, China.
Department of Pathology, Peking University Cancer Hospital, Beijing, China.
Front Oncol. 2024 Aug 30;14:1412225. doi: 10.3389/fonc.2024.1412225. eCollection 2024.
Epithelioid inflammatory myofibroblastic sarcoma (EIMS) is an extremely rare and aggressive form of inflammatory myofibroblastic tumor. Clinically, it has a high risk of relapse and peripheral organ infiltration, and it responds poorly to conventional chemotherapy. Anaplastic lymphoma kinase (ALK) inhibitors are currently the most effective targeted therapy for EIMS. This report discusses a typical case of abdominal EIMS in a 43-year-old woman. The tumors recurred rapidly within one month after surgery. Alectinib was promptly administered upon diagnosis. However, the patient developed a severe allergic reaction to the medication. After a comprehensive assessment and symptomatic treatment, her condition stabilized, leading to a favorable prognosis. This study summarizes cases of abdominal EIMS, highlights the successful use of Alectinib for treatment, and discusses the management of medication-related complications.
上皮样炎性肌成纤维细胞肉瘤（EIMS）是炎性肌成纤维细胞肿瘤中一种极其罕见且侵袭性强的类型。临床上，它具有高复发风险和外周器官浸润风险，且对传统化疗反应不佳。间变性淋巴瘤激酶（ALK）抑制剂是目前治疗EIMS最有效的靶向治疗药物。本报告讨论了一名43岁女性腹部EIMS的典型病例。肿瘤在手术后一个月内迅速复发。诊断后立即给予阿来替尼治疗。然而，患者对该药物出现了严重过敏反应。经过全面评估和对症治疗，她的病情稳定下来，预后良好。本研究总结了腹部EIMS病例，强调了阿来替尼治疗的成功应用，并讨论了药物相关并发症的处理。
